Brief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
20/08/2026 18:38
BRIEF-Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis Aug 20 (Reuters) - Arcutis Biotherapeutics, Inc. ARQT.O:
ARCUTIS CANADA: PRZORYVE CREAM 0.05% RECEIVES HEALTH CANADA APPROVAL FOR CHILDREN AGED 2 TO 5 YEARS WITH MILD TO MODERATE ATOPIC DERMATITIS
Source text: ID:nCNWgmy9Wa
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4